The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 11, 2025
Filed:
Oct. 10, 2023
Applicants:
Allogene Therapeutics, Inc., South San Francisco, CA (US);
Les Laboratoires Servier, Suresnes, FR;
Inventors:
Cyril Alkis Konto, San Francisco, CA (US);
Amina Zinai, Paris, FR;
Assignees:
Allogene Therapeutics, Inc., South San Francisco, CA (US);
Les Laboratoires Servier, Suresnes, FR;
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 31/664 (2006.01); A61K 31/7076 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 14/70578 (2013.01); A61K 31/664 (2013.01); A61K 31/7076 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/001102 (2018.08); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 16/2803 (2013.01); C07K 16/2893 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2239/23 (2023.05); A61K 2239/26 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2300/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2506/11 (2013.01);
Abstract
The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.